HUTCHMED (00013) released its annual performance with a net profit attributable to shareholders of $457 million USD, representing a year-on-year growth of 1111.03%.

HUTCHMED (00013) announced its full-year performance for 2025, with a total revenue of $549 million, a decrease of 12.96% year-on-year. Shareholders' net profit was $457 million, an increase of 1111.03% year-on-year, with a basic earnings per share of $0.53. Dr. Dan Eldar, non-executive chairman of HUTCHMED, said, "Our team's scientific expertise in the field of innovative drug development, combined with the assistance of advanced artificial intelligence (AI) tools, has positioned HUTCHMED at the forefront of exploring novel treatment mechanisms. Leveraging this leading position, we continue to actively explore new technologies, products, and targets to enrich our product portfolio and make good use of our robust financial reserves. Our business development team has received interest from multiple multinational pharmaceutical companies to collaborate on advancing innovative drug candidates with global market leadership potential through partnerships. These potential collaborations will further validate the scientific value and commercial potential of our innovative platform, allowing HUTCHMED to leverage the expertise of partners in global development and marketing to accelerate the global advancement of innovative drugs to address unmet medical needs. FRUZAQLA has successfully validated this strategy, and we will also extend this strategy to our ATTC technology, expecting to see initial results this year. The company is at a crucial turning point. We have adjusted the positioning of our commercial team to better address current challenges and drive sales growth in the Chinese market, showing significant results in the second quarter of 2025. For later pipeline projects, our Phase III studies have yielded encouraging clinical results supporting new drug applications, and we have accumulated extensive experience in obtaining approvals from mainstream regulatory agencies. Additionally, our large molecule technology platform has smoothly transitioned from drug discovery to clinical development, with two candidate drugs entering clinical trials. We believe this is a significant development opportunity for HUTCHMED, not only deepening collaboration with leading global industry players but also increasing research and development investment to accelerate the realization of the platform's broad therapeutic potential."